Geneva, Aug. 6 -- International Clinical Trials Registry received information related to the study (ChiCTR2600128652) titled 'Adebrelimab Plus Apatinib and SOX as Conversion Therapy in Borderline resectable gastric cancer (BRGC): A Single-Arm, Phase II Exploratory Study' on July 23.
Study Type: Interventional study
Study Design:
Single arm
Primary Sponsor: Shandong Provincial Hospital
Condition:
gastric cancer
Intervention:
Treatment group:Adebenone 1200 mg, IV drip, Day 1, every 3 weeks
Tegafur 40 mg/m^2, daily, Days 1-14, every 3 weeks
Oxaliplatin 130 mg/m^2, IV drip, Day 1, every 3 weeks
Apatinib 250 mg, daily
a total of 4 cycles, with apatinib discontinued on the last 28 days.
After conversion therapy, the patient underwent s...